In HTA-driven environments, stability in reimbursement positioning often reflects persistence of structural constraints rather than absence of progress. Following a structured surveillance reassessment, the MARA Rating for baxdrostat in treatment-resistant
Brensocatib, poised for its first FDA decision in non-cystic fibrosis bronchiectasis, shows clear clinical benefits but faces major U.S. market access challenges. We examine Phase 3 ASPEN trial results, safety
Market Access Risk Assessment MARA Rating Company Obesity drives ≈ $173 billion in direct U.S. medical costs each year (2019 USD). Four next‑generation pipeline assets—Survodutide, Retatrutide, Orforglipron and the amylin/GLP‑1 co‑formulation Cagrilintide + Semaglutide (“CagriSema”)—promise weight‑loss efficacy
Caution Flags Raised: MARA Rating (B++) Spots Access Risks in Merck’s $10B Verona Deal Merck Acquires Verona Pharma for $10B – Our B++ MARA Rating Warns of Access Hurdles Merck